HIF1A-AS2 predicts poor prognosis and regulates cell migration and invasion in triple-negative breast cancer.
The aberrant expression of hypoxia-inducible factor 1 alpha (HIF1A)-antisense RNA 2 (HIF1A-AS2) was found in various human cancers including breast cancer. The aim of this study was to present more evidence about the role HIF1A-AS2 on triple-negative breast cancer (TNBC). In our results, HIF1A-AS2 was also found to be upregulated in TNBC tissues compared with non-TNBC tissues or adjacent normal tissues. Besides, HIF1A-AS2 expression was also elevated in TNBC cell lines compared with the normal breast epithelial cell line. Moreover, high expression of HIF1A-AS2 was associated with lymph node metastasis, distant metastasis and unfavorable histological grade in TNBC patients. Survival analysis showed a TNBC patient with high HIF1A-AS2 expression had shorter overall survival than patients with low HIF1A-AS2 expression, and HIF1A-AS2 high expression acted as an independent poor prognostic factor for overall survival in TNBC patients. The cell migration and invasion assays suggested inhibition of HIF1A-AS2 obviously depressed TNBC cell migration and invasion. In conclusion, HIF1A-AS2 serves as a novel biomarker for predicting clinical progression and prognosis in TNBC.
['Wang|Yufei|Y|', 'Zhang|Guochao|G|', 'Han|Jie|J|0000-0001-6388-9749']
D045744:Cell Line, Tumor D002465:Cell Movement D005260:Female D015972:Gene Expression Regulation, Neoplastic D006801:Humans D008207:Lymphatic Metastasis D008875:Middle Aged D011379:Prognosis D062085:RNA, Long Noncoding D064726:Triple Negative Breast Neoplasms
breast cancer hypoxia-inducible factor 1 alpha (HIF1A)-antisense RNA 2 (HIF1A-AS2) biomarker long noncoding RNA (lncRNA)